Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00212407 · ClinicalTrials.gov registry record · Early Phase 1

New York Blood Center National Cord Blood Program

A Early Phase 1 study, sponsored by New York Blood Center.

Terminated
Registry status
Early Phase 1
Development phase
4,476
Enrollment target

NCT00212407 is a Early Phase 1 study that was terminated before completion, run by New York Blood Center. The registered enrollment target is 4,476 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00212407, a Early Phase 1 study, was terminated before completion, sponsored by New York Blood Center.

TERMINATED
Registry status
Early Phase 1
Development phase
4,476 participants
Enrollment target

Study Summary

Umbilical cord blood is used as a source of hematopoietic stem cells for bone marrow reconstitution in patients who would be potential candidates for a bone marrow transplant from an unrelated marrow donor. The outcome of transplantation is obtained to assess cord blood myeloid and platelet engraftment, transplant related mortality, overall survival, graft vs. host disease and, for patients with leukemia, lymphoma or myelodysplasia, relapse.

Interventions

  • BIOLOGICAL Umbilical Cord Blood Transplantation

Trial Details

FieldValue
Enrollment Target 4,476 participants
Start Date 1993-02
Est. Completion 2011-11-10
Phase Early Phase 1

Sponsor

New York Blood Center

4 total trials

What the Registry Record Tells You About NCT00212407

The ClinicalTrials.gov registry entry for NCT00212407 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 4,476 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Blood Center, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Umbilical Cord Blood Transplantation is the first listed.

NCT00212407 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00212407 about?

NCT00212407 is a clinical study titled "New York Blood Center National Cord Blood Program". Umbilical cord blood is used as a source of hematopoietic stem cells for bone marrow reconstitution in patients who would be potential candidates for a bone marrow transplant from an unrelated marrow donor. The outcome of transplantation is obtained to assess cord blood myeloid and platelet engraftm...

What is the current status of trial NCT00212407?

This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 4,476 participants. The study started on 1993-02. Estimated completion is 2011-11-10.

What interventions are being tested in trial NCT00212407?

The interventions under investigation include: Umbilical Cord Blood Transplantation (BIOLOGICAL).

Who is sponsoring clinical trial NCT00212407?

This trial is sponsored by New York Blood Center, which has 4 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.